Corcept Ties ALS Drug to Improved 2-Year Survival as Phase 3 Start Date Nears

Why It Matters

If the Phase 3 trial validates the survival advantage, dazucorilant could become the first disease‑modifying treatment for ALS, reshaping a market with few effective options and driving significant biotech valuation upside.

Key Takeaways

• Dazucorilant 300 mg cut two‑year ALS death risk by ~87%.
• Phase 2 showed no motor improvement, but survival signal prompted extension.
• High-dose caused 58% discontinuations due to GI side effects.
• Corcept plans Phase 3 trial this year, incorporating dose‑titration data.
• Earlier relacorilant failure highlights shift to cortisol modulation strategy.

Pulse Analysis

Amyotrophic lateral sclerosis remains one of the most lethal neurodegenerative diseases, with median survival barely exceeding three years after diagnosis. Traditional approaches have focused on slowing motor decline, yet no therapy has convincingly extended life expectancy. Corcept Therapeutics’ strategy diverges by targeting cortisol pathways with dazucorilant, a selective glucocorticoid receptor modulator. By dampening the stress hormone’s impact on neuronal inflammation, the drug aims to address a root cause of ALS progression rather than merely managing symptoms, positioning it as a potentially disease‑modifying candidate.

The Phase 2 trial enrolled 249 participants and compared two dosages of dazucorilant against placebo. While the primary endpoint—motor function after 24 weeks—was not met, the study uncovered a striking survival signal: none of the 83 patients receiving the 300 mg dose died during the initial period, versus five deaths in the placebo arm. Extended follow‑up showed an 87% reduction in two‑year mortality risk for the high‑dose group, albeit with a 58% discontinuation rate driven by gastrointestinal adverse events. Corcept’s ongoing dose‑titration study seeks to mitigate these tolerability issues, a critical step before advancing to a larger pivotal trial.

Looking ahead, the upcoming Phase 3 trial will test the 300 mg dose with a placebo control, integrating insights from the titration study to improve patient adherence. Success could catapult dazucorilant into a market currently dominated by supportive care, offering investors a rare high‑growth opportunity in neuro‑degeneration. Moreover, the data may stimulate broader interest in cortisol modulation as a therapeutic avenue, potentially influencing research pipelines across multiple neuro‑inflammatory conditions.